Search Results

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) announces that it has entered into an agreement with Oak Hill Financial Inc. (“Oak Hill”) to provide business

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (“OHAM”), an Exempt Market Dealer to provide capital markets advice related to the Company’s capital markets strategy.

Benson Hill, Inc. (NYSE:BHIL, the “Company” or “Benson Hill”), an ag-tech company unlocking the natural genetic diversity of plants, today announced operating and financial results for the year ended December 31, 2023.

7 Hills Pharma Inc., a clinical-stage pharma company leveraging a novel mechanism of action to safely enhance the effectiveness of cancer immunotherapies, was awarded $4.7 million from the Cancer Prevention and Research Institute of Texas to support its cell/gene therapy development program.

Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), an ag tech company unlocking the natural genetic diversity of plants, announced today that it will release its financial results for the full year and fourth quarter ending Dec. 31, 2023, before the market opens on Thursday, March 14, 2024.

Oak Hill Bio and Chiesi announced that the first patient has been enrolled in a resumed Phase 2b clinical study to assess the efficacy and safety of OHB-607, an investigational drug candidate being developed to treat complications of extremely premature birth, including bronchopulmonary dysplasia, a serious condition for which there are no approved therapies.

Benson Hill, Inc., an ag tech company unlocking the natural genetic diversity of plants, announced that recent advances in its soybean breeding program will drive the doubling of its seed portfolio by 2025.

Kiromic BioPharma, Inc. announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study.

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, announced the appointment of Emily Hill as Chief Financial Officer.